Compare CULP & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CULP | PRPO |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 40.1M |
| IPO Year | 1994 | 2000 |
| Metric | CULP | PRPO |
|---|---|---|
| Price | $3.60 | $23.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 25.0K | ★ 85.7K |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.06 | ★ 92.15 |
| EPS | N/A | N/A |
| Revenue | ★ $203,482,000.00 | $24,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $2.70 | $13.80 |
| 52 Week High | $4.75 | $33.63 |
| Indicator | CULP | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 45.09 |
| Support Level | $3.38 | $22.36 |
| Resistance Level | $3.60 | $25.98 |
| Average True Range (ATR) | 0.20 | 1.94 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 49.06 | 11.58 |
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.